Projects per year
Personal profile
Personal profile
Dr. Li finished his medical school at Beijing Medical University and his graduate school at Penn State. He had his postdoctoral training at Stanford University before joining the Research Institute in late 2017.
Research interests
Dr. Li's research interest includes 1) non-genetic mechanisms of therapeutic resistance, and 2) rational combination therapy. Dr. Li's lab utilizes both experimental and computational approaches to study cancer biology and therapeutics.
Research Area Keywords
- Cancer
Free-text keywords
- Combination therapy
- Chemoresistance
- CRISPR
- Differentiation
- Proteomics in oncology
Fingerprint
Dive into the research topics where Yulin Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Active
-
-
The Role of Suv420h1 Histone Methyltransferase in MYC-Driven Tumorigenesis
9/8/17 → 8/31/21
Project: Federal Funding Agencies
-
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y. & Li, Y., Dec 2021, In: BMC Cancer. 21, 1, 237.Research output: Contribution to journal › Article › peer-review
Open Access -
Selective Labeling and Identification of the Tumor Cell Proteome of Pancreatic Cancer In Vivo
Azizian, N. G., Sullivan, D. K., Nie, L., Pardo, S., Molleur, D., Chen, J., Weintraub, S. T. & Li, Y., Dec 8 2020, (E-pub ahead of print) In: Journal of Proteome Research.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
XPO1-dependent nuclear export as a target for cancer therapy
Azizian, N. G., Azizian, N. G., Li, Y. & Li, Y., Jun 1 2020, In: Journal of Hematology and Oncology. 13, 1, 61.Research output: Contribution to journal › Review article › peer-review
21 Scopus citations -
Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index
Li, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W. & Dill, D. L., Nov 14 2019, In: Scientific Reports. 9, 1, p. 16775Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Rational targeted therapeutics for double-hit lymphoma
Azizian, N. G., Liu, Y., Pham, L. V. & Li, Y., Aug 21 2019, In: International Journal of Hematologic Oncology. 8, 3, p. IJH19Research output: Contribution to journal › Article › peer-review